Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04640337
Other study ID # 1264955
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 16, 2020
Est. completion date March 20, 2024

Study information

Verified date May 2023
Source University of Valencia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main aim of this study is to verify the influence of placebo on the effectiveness of Intratissue Percutaneous Electrolysis (IPE) in patients suffering from with chronic patellar tendinopathy (PT). The secondary aim is to investigate the possible influence of the IPE on pain perception and conditioned pain modulation (CPM) in patients with chronic PT.


Description:

The aim of this study is to investigate the influence of placebo on the effectiveness of Intratissue Percutaneous Electrolysis (IPE) in patients with chronic PT. For this purpose a randomized clinical trial will be carried out, with a sample of patients diagnosed of chronic PT based on signs, symptoms and clinical examination. Subjects will be randomly allocated to four different groups: group E1, IPE will be applied, participants will believe they are receiving IPE; group E2, IPE will be applied, participants will believe they are receiving placebo; group P1, IPE will not be applied, participants will believe they are receiving IPE; and group P2, IPE will not be applied, participants will believe they are receiving placebo. IPE treatment will consist of a total of 3 sessions, with a time interval of one week between the 1st and 2nd sessions and 2 weeks between the 2nd and 3rd sessions. To evaluate the effect of intervention, the subjects will be assessed at baseline (V0), one week after the end of the intervention (V1) and 3 weeks after the intervention (V2). In V0, sociodemographic (sex, age, profession, height, body mass index (BMI), sport activity, hours of sport per week) and clinical data (associated pathologies, affected lower limb, dominant lower limb, duration of symptoms) will be registered. In each assessment time information regarding BMI, sports activity, hours of sport per week and location of pain will be obtained. Moreover, in all assessments participants were evaluated for four physical performance tests, pain and functional scales, ultrasound examination, pressure pain thresholds, conditioned pain modulation, and expectations questionnaires.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 20, 2024
Est. primary completion date December 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years old or older - presenting the following signs and symptoms of patellar tendinopathy: pain when jumping, landing, running o changing direction, pain at the inferior pole of the patella, Victorian Institute of Sport Assessment-Patella (VISA-P) score <80, symptoms duration of at least 3 months. Exclusion Criteria: - prior knee surgery - patients having received local corticosteroids injection in the tendon within the preceding 6 months - patients presenting any inflammatory disease, metabolic bone disease, type II diabetes, fibromyalgia, hypercholesterolemia, pregnancy or chemotherapy within the 3 months prior to the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
IPE applied, participants believe they are receiving IPE
Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.
IPE applied, participants believe they are receiving placebo
Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie
IPE not applied, participants believe they are receiving IPE
Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th
IPE not applied, participants believe they are receiving placebo
Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.

Locations

Country Name City State
Spain Mercè Balasch i Bernat Valencia

Sponsors (1)

Lead Sponsor Collaborator
University of Valencia

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain intensity Knee pain intensity reported by the patient will be assessed using a 100-mm visual analogue scale (VAS, 0-100, 0=minimum score, 100=maximum score). Higher values represent a better outcome (less pain). Baseline
Primary Pain intensity Knee pain intensity reported by the patient will be assessed using a 100-mm visual analogue scale (VAS, 0-100, 0=minimum score, 100=maximum score). Higher values represent a better outcome (less pain). One week post-intervention
Primary Pain intensity Knee pain intensity reported by the patient will be assessed using a 100-mm visual analogue scale (VAS, 0-100, 0=minimum score, 100=maximum score). Higher values represent a better outcome (less pain). Three weeks post-intervention
Primary Patellar tendon function Victorian Institute of Sport Assessment-Patellar Tendon (VISA-P, 0-100, 0=minimum score, 100=maximum score) will aso be used to evaluate function of the patellar tendon. A score between 80-100 points is considered as the optimal outcome. Baseline
Primary Patellar tendon function Victorian Institute of Sport Assessment-Patellar Tendon (VISA-P, 0-100, 0=minimum score, 100=maximum score) will aso be used to evaluate function of the patellar tendon. A score between 80-100 points is considered as the optimal outcome. One week post-intervention
Primary Patellar tendon function Victorian Institute of Sport Assessment-Patellar Tendon (VISA-P, 0-100, 0=minimum score, 100=maximum score) will aso be used to evaluate function of the patellar tendon. A score between 80-100 points is considered as the optimal outcome. Three weeks post-intervention
Primary Physical performance of the knee Physical performance of the knee will be assessed by the Single Leg Decline squat (SLDS), which consists of performing a squat with one leg on a decline board with an angle of 25º. Baseline
Primary Physical performance of the knee Physical performance of the knee will be assessed by the Single Leg Decline squat (SLDS), which consists of performing a squat with one leg on a decline board with an angle of 25º. One week post-intervention
Primary Physical performance of the knee Physical performance of the knee will be assessed by the Single Leg Decline squat (SLDS), which consists of performing a squat with one leg on a decline board with an angle of 25º. Three weeks post-intervention
Primary Cross-sectional area (CSA) of the patellar tendon CSA at rest, with a knee flexion of 20º, will be measured by ultrasonography. Baseline
Primary Cross-sectional area (CSA) of the patellar tendon CSA at rest, with a knee flexion of 20º, will be measured by ultrasonography. One week post-intervention
Primary Cross-sectional area (CSA) of the patellar tendon CSA at rest, with a knee flexion of 20º, will be measured by ultrasonography. Three weeks post-intervention
Primary Presence of neovascularity of the patellar tendon The presence (yes/no) of neovascularity of the patellar tendon will be measured by ultrasonography. Baseline
Primary Presence of neovascularity of the patellar tendon The presence (yes/no) of neovascularity of the patellar tendon will be measured by ultrasonography. One week post-intervention
Primary Presence of neovascularity of the patellar tendon The presence (yes/no) and amount (0=no vascularity, 1=low fow, 2=mild flow, 3=high flow) of neovascularity of the patellar tendon will be measured by ultrasonography. Three weeks post-intervention
Primary Amount of neovascularity of the patellar tendon The amount (0=no vascularity, 1=low fow, 2=mild flow, 3=high flow) of neovascularity of the patellar tendon will be measured by ultrasonography. Baseline
Primary Amount of neovascularity of the patellar tendon The amount (0=no vascularity, 1=low fow, 2=mild flow, 3=high flow) of neovascularity of the patellar tendon will be measured by ultrasonography. One week post-intervention
Primary Amount of neovascularity of the patellar tendon The amount (0=no vascularity, 1=low fow, 2=mild flow, 3=high flow) of neovascularity of the patellar tendon will be measured by ultrasonography. Three weeks post-intervention
Secondary Pressure Pain Thresholds (PPT) PPTs will be recorded using an electronic algometer at the ipsilateral (affected) patellar tendon, the contralateral patellar tendon and the ipsilateral upper trapezius. Higher values represent a better outcome. Baseline
Secondary Pressure Pain Thresholds (PPT) PPTs will be recorded using an electronic algometer at the ipsilateral (affected) patellar tendon, the contralateral patellar tendon and the ipsilateral upper trapezius. Higher values represent a better outcome. One week post-intervention
Secondary Pressure Pain Thresholds (PPT) PPTs will be recorded using an electronic algometer at the ipsilateral (affected) patellar tendon, the contralateral patellar tendon and the ipsilateral upper trapezius. Higher values represent a better outcome. Three weeks post-intervention
Secondary Conditioned pain modulation (CPM) CPM will be tested using the upper extremity submaximal effort tourniquet test. Baseline
Secondary Conditioned pain modulation (CPM) CPM will be tested using the upper extremity submaximal effort tourniquet test. One week post-intervention
Secondary Conditioned pain modulation (CPM) CPM will be tested using the upper extremity submaximal effort tourniquet test. Three weeks post-intervention
Secondary Patients' expectations Patients' expectations with the treatment will be registered using an add-hoc questionnaire consisting of 2 questions: "What do you think will be the intensity of your pain when this intervention takes effect?" (NPRS, 0-10, 10 severe pain, 0=no pain) and "Do you expect to have more pain, less pain or the same intensity of pain after treatment?" (more pain, less pain, same pain). Baseline
Secondary Self-perceived change with the treatment Participants' will rate the results/outcomes obtained with the treatment by the Global rating of change scale (GROC) ((-7)-(+7), -7= very great deal worse, +7= very great deal better). One week post-intervention
Secondary Self-perceived change with the treatment Participants' will rate the results/outcomes obtained with the treatment by the Global rating of change scale (GROC) ((-7)-(+7), -7= very great deal worse, +7= very great deal better). Three weeks post-intervention
Secondary Self-perceived pain after treatment Self-perceived pain after treatment will be assessed by the question "What do you think your pain is like now (after treatment): more pain, less pain or the same pain intensity compared to before treatment?" (more pain, less pain, same pain). One week post-intervention
Secondary Self-perceived pain after treatment Self-perceived pain after treatment will be assessed by the question "What do you think your pain is like now (after treatment): more pain, less pain or the same pain intensity compared to before treatment?" (more pain, less pain, same pain). Three weeks post-intervention
See also
  Status Clinical Trial Phase
Recruiting NCT06056440 - Efficacy of a Physical Rehabilitation Program Using Virtual Reality in Patients With Chronic Tendinopathy (Virtendon-Rehab) N/A
Recruiting NCT06381492 - Quantifying Patellar Tendon Microstructure Using DTI
Enrolling by invitation NCT06102421 - Evaluation of the Effectiveness of Extracorporeal Shockwave Therapy in Patients With Patellar Tendinopathy on Its Micromorphology
Completed NCT03096067 - Patellar Tendinopathy - The Effect of Load Magnitude in Exercise-based Treatment N/A
Terminated NCT02116946 - Plasma Injections Plus Exercise for Patellar Tendinopathy Phase 2
Recruiting NCT05731037 - Influence of Restitution Time in Treatment of Patellar Tendinopathy N/A
Completed NCT03694730 - Continued Activity During Rehabilitation in Patients With Patellar Tendinopathy N/A
Completed NCT01111773 - Study Evaluating a Heated Lidocaine and Tetracaine Topical Patch in the Treatment of Patients With Patellar Tendinopathy Phase 2
Active, not recruiting NCT04753853 - Stromal Vascular Fraction (SVF) Injection in the Treatment of Patellar Tendinopathy N/A
Terminated NCT03196063 - Effectiveness of Two Exercise Protocols in the Treatment of Patients With Patellar Tendinopathy N/A
Completed NCT01460004 - The Effect of Infrapatellar Strap Treatment on Pain Extent and Athletic Measures in Young Athletes N/A
Completed NCT04650997 - The Mechanical,Physiological and Therapeutic Effects of Eccentric Exercise Combined With Extracorporeal Shockwave Therapy in Athletes With Patellar Tendinopathy N/A
Not yet recruiting NCT04204460 - Electromyographic Evaluation of Quadriceps During Eccentric Decline Squat
Active, not recruiting NCT03454737 - Treatment of Refractory Patellar Tendinopathy With Mesenquimal Trunk Cells. Comparative Study With PRP. N/A
Completed NCT06199583 - Diagnostic Value of Shear-Wave Elastography for Patellar Tendinopathy
Active, not recruiting NCT04550013 - Blood Flow Restriction Training for Treatment of Chronic Patellar Tendinopathy N/A
Recruiting NCT05407194 - Effect of Collagen/Vitamin C in Jumper's Knee; a RCT N/A